



NHMRC Centre for Blood Transplant and Cell Therapy

Supported by Leukaemia Foundation

The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, investigators from the CBTCT will review major topics in stem cell transplantation and cell therapy, highlighting how the activities of the CBTCT are addressing current challenges in stem cell transplantation. Following on in this series, Professor David Curtis from the Alfred Hospital in Melbourne will review the role of post-transplant cyclophosphamide for the prevention of graft versus host disease following allogeneic blood transplant. Mr Mingdi Xie, who is the current MAGIC Australia Project coordinator for the CBTCT, will then present an introduction to the MAGIC consortium, including its functions and importance in allogeneic blood transplant research

Speakers



Professor David Curtis

The Alfred Hospital and
Monash University

*Post-transplant cyclophosphamide
as graft vs host disease prophylaxis
after allogeneic blood transplant*



Mr Mingdi Xie

The Royal Melbourne
Hospital and Peter
MacCallum Cancer Centre

*The MAGIC Consortium –
What is it and what it does*

WEBINAR

Centre for Blood Transplant and Cell Therapies Webinar Series

Thursday 20 August 2020
8am

ALL WELCOME TO ATTEND

JOIN WEBINAR

<https://bloodcelltherapy.org.au/>

